Efficacy and safety of an mRNA-based RSV preF vaccine in preclinical studies
Huarong Bai, Qin Li, Yue Gao, Yubin Zhao, Xueliang Yu, Rongkuan Hu
This paper evaluates an mRNA-based RSV preF vaccine, STR-V003, showing robust immunogenicity, safety, and protective immunity in preclinical studies, leading to FDA approval for phase I clinical trials.
Vaccines · Jun 10, 2025Peer-reviewedPharmacology & Toxicology